American Journal of Clinical Nutrition, Vol 67, 716-721, Copyright © 1998 by The American Society for Clinical Nutrition, Inc

ORIGINAL RESEARCH COMMUNICATIONS

Bioavailability of phylloquinone from an intravenous lipid emulsion

ME Camilo, A Jatoi, M O'Brien, K Davidson, L Sokoll, JA Sadowski and JB Mason
Vitamin K Laboratory, The Jean Mayer US Department of Agriculture Human Nutrition Research Center on Aging at Tufts University, Boston, USA.

This randomized, controlled study evaluated the bioavailability of phylloquinone from an intravenous lipid emulsion. A mild vitamin K deficiency was induced in 12 healthy adult men and women by dietary restriction of phylloquinone (40 microg/d, days 1-11) and by administration of warfarin (1.0 mg/d, days 5-11). On day 11, subjects received a 500-mL intravenous solution of either lipid or saline, both of which contained 154 microg phylloquinone. Bioavailability was assessed by serial measurements of plasma phylloquinone, vitamin K1-2,3- epoxide. PIVKA-II (proteins induced by vitamin K absence or antagonists- II), and percentage undercarboxylated osteocalcin. As a result of vitamin K deficiency and minidose warfarin, vitamin K1-2,3-epoxide, PIVKA-II, and percentage undercarboxylated osteocalcin increased significantly between days 1 and 11 (P = 0.05, 0.016, and 0.001, respectively). With the infusions, plasma phylloquinone increased in both groups (P = 0.001). After the infusions vitamin K,-2,3-epoxide decreased in both groups (P = 0.002). Changes in plasma phylloquinone and vitamin K1-2,3-epoxide were no different in the two groups (mean areas under the curves +/- SEM: 116+/-13 nmol x h/L for the saline group and 102+/-20 nmol x h/L for the lipid group for phylloquinone; 38.6+/-7.5 nmol x h/L for the saline group and 31.3+/-9.0 nmol x h/L for the lipid group for vitamin K1-2,3-epoxide). PIVKA-II decreased significantly from baseline values (P = 0.005) in both groups after the infusions. Intravenous lipid reversed the effects of minidose warfarin and of dietary restriction of phylloquinone on hemostasis and vitamin K nutritional status. This reversal was no different from that seen with the infusion of phylloquinone in a saline solution.

This article has been cited by other articles:

				M. Ferrone and M. Geraci A Review of the Relationship Between Parenteral Nutrition and Metabolic Bone Disease Nutr Clin Pract, June 1, 2007; 22(3): 329 - 339. [Abstract] [Full Text] [PDF]

				L. J. Schurgers, K. J. F. Teunissen, K. Hamulyak, M. H. J. Knapen, H. Vik, and C. Vermeer Vitamin K-containing dietary supplements: comparison of synthetic vitamin K1 and natto-derived menaquinone-7 Blood, April 15, 2007; 109(8): 3279 - 3283. [Abstract] [Full Text] [PDF]

				M. Bern Observations on Possible Effects of Daily Vitamin K Replacement, Especially Upon Warfarin Therapy JPEN J Parenter Enteral Nutr, November 1, 2004; 28(6): 388 - 398. [Abstract] [Full Text] [PDF]

				S. L Booth, M. E O'Brien-Morse, G. E Dallal, K. W Davidson, and C. M Gundberg Response of vitamin K status to different intakes and sources of phylloquinone-rich foods: comparison of younger and older adults Am. J. Clinical Nutrition, September 1, 1999; 70(3): 368 - 377. [Abstract] [Full Text] [PDF]